NON-US ONCOLOGY
Your Premier Analytics Source for Real-World Oncology Data in Europe
TriNetX offers non-US oncology real-world data services to help our partners show evidence of treatment value, fit for regulatory submission and publication, with timely, representative, longitudinal cancer care data in Europe.
We help our partners show evidence of treatment value, fit for regulatory submission and publication, with timely, representative, longitudinal cancer care data in Europe.
TherapyMonitor™: Non-US Oncology Analysis Reports
Get comprehensive analyses derived from the latest longitudinal physician-supplied data on European oncology care. Collaborating with medical experts and pharmaceutical leaders, our European-based TriNetX Oncology team tailors report specifications for precise study objectives in oncological and rare-disease indications. Unearth complete, representative, and high-quality data, offering valuable insights into disease prevalence, treatment patterns, and market dynamics across the continent.
External Control Arms Design & Execution
TriNetX External Control Arms (ECAs) provide a proven methodology to create comparison cohorts without the high costs and lengthy timelines associated with traditional methods. TriNetX ECAs enable teams to generate control data that is representative and fit-for-purpose, enhancing clinical studies and regulatory submissions.
HTA Regulatory Support
TriNetX’s epidemiological services deliver evidence-based analysis and representative data so you can facilitate more informed decision-making, enhance your targeting and sampling efforts, and more deeply examine health outcomes. Backed by our strong record of successful HTA submissions, the breadth of our publication history, the depth of the TriNetX team’s experience, and the power of our data partnership with physicians and healthcare providers, you know you are in good hands.
Ongoing TherapyMonitor Projects
Stay Ahead with Quarterly Updates
TherapyMonitor provides regulatory-grade reports refreshed every 3 months, delivering up-to-date insights into patient data and outcomes. Leading healthcare innovation, our cutting-edge analyses shape critical decision-making processes.
TherapyMonitor analyses are regularly utilized for:
Health Technology Assessment & Epidemiology
Gain invaluable insights for health technology assessments and epidemiological studies supported by evidence-based data for informed decisions.
External Control Arms for Early & Accelerated Market Authorization
Access robust external control arms for accelerated market authorization, streamlining approval processes for novel therapies.
Current Insights in Therapy Algorithms, Patient- and Disease Characteristics, Care Pathway- and Outcomes Analyses
Dive into in-depth insights on therapy algorithms, patient and disease characteristics, care pathways, and outcomes analyses. Our expertly researched reports are often showcased at top medical conferences.
| INDICATION | COUNTRIES | SINCE |
|---|---|---|
| Breast Cancer | Germany | 2024 |
| Chronic Lymphocytic Leukemia (CLL) | Germany, Spain | 2021 |
| Multiple Myeloma (MM) | Germany, Spain | 2016 (Germany), 2023 (Spain) |
|
Urothelial Cancer |
Germany | 2023 |
TriNetX Contact Information for Physicians in Europe
Download a Hematology TherapyMonitor Sample
TherapyMonitor
TherapyMonitor is scalable regarding indication and region, allows for fit-for-purpose research focused on specific target populations, and is based on fully anonymized data.
Inside you’ll discover insights on:
- Baseline/Demographics
- Current Therapy Status
- Initial Diagnosis
- Induction Therapy (for each line of treatment)
- Stem Cell Transplantation Measures (for each line of treatment)
- CAR-T Therapy Measures (for each line of treatment)
- Supportive Therapy and Adverse Event Prophylaxis (for each line of treatment)
- Best Achieved Outcomes/Response Assessments (for each line of treatment)
Explore Real-World Oncology Research in Europe
See how TriNetX is transforming oncology research across Europe. Discover how real-world data can accelerate clinical research and advance patient care.
Going Beyond What’s Possible
As a global force, TriNetX continues to navigate uncharted territories with an unwavering commitment to revolutionizing the healthcare ecosystem.
Far beyond being a repository of information, TriNetX serves as a strategic partner in connecting health systems, providers, and researchers worldwide through our extensive real-world patient data that runs a mile wide and a mile deep.
From trial operations to evidence generation, we put you at the forefront of discovery.
Clinical Trial Design & Optimization
Data Sets & Analytics
Non-US Oncology
Real-World Evidence Generation
Pharmacovigilance & Drug Safety
TriNetX Oncology GmbH is a wholly owned subsidiary of TriNetX, LLC.
TriNetX Contact Information for Physicians in Europe:
Tel: +49 761 – 38 39 94 – 0 | Fax: +49 761 – 20 25 117 | oncology@trinetx.com
Complete the form below to access a sample TriNetX Oncology GmbH TherapyMonitor Report:
"*" indicates required fields